NewsBenzingaCerenome Announced Interim Data From Its Ongoing ReSPECT-LM Study Of Repeated Intraventricular Dosing Of REYOBIQ; No Dose-Limiting Toxicities Or Adverse Events Leading To Treatment Discontinuation Have Been Reported Cerenome Announced Interim Data From Its Ongoing ReSPECT-LM Study Of Repeated Intraventricular Dosing Of REYOBIQ; No Dose-Limiting Toxicities Or Adverse Events Leading To Treatment Discontinuation Have Been Reported Benzinga 2026.11.16 12:32 (GMT+0) Open on Benzinga Other news TD Cowen Maintains Buy on Netskope, Raises Price Target to $25 TD Cowen Maintains Buy on Navan, Raises Price Target to $32 TD Cowen Maintains Hold on NextDecade, Raises Price Target to $7.5 Corvex Secures $103M Nvidia Blackwell AI Computing Deal TD Cowen Maintains Buy on Milestone Pharmaceuticals, Lowers Price Target to $5 Helus Pharma Touts Positive Data for Depression Drug